- Home
- ATEX vs KROS Comparison
ATEX vs KROS Comparison
Compare ATEX & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATEX
- KROS
- Stock Information
- Founded
- ATEX 1997
- KROS 2015
- Country
- ATEX United States
- KROS United States
- Employees
- ATEX N/A
- KROS N/A
- Industry
- ATEX Telecommunications Equipment
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- ATEX Telecommunications
- KROS Health Care
- Exchange
- ATEX Nasdaq
- KROS Nasdaq
- Market Cap
- ATEX 555.0M
- KROS 461.6M
- IPO Year
- ATEX N/A
- KROS 2020
- Fundamental
- Price
- ATEX $37.35
- KROS $11.47
- Analyst Decision
- ATEX Buy
- KROS Buy
- Analyst Count
- ATEX 2
- KROS 11
- Target Price
- ATEX $64.00
- KROS $30.00
- AVG Volume (30 Days)
- ATEX 242.6K
- KROS 953.9K
- Earning Date
- ATEX 02-11-2025
- KROS 05-07-2025
- Dividend Yield
- ATEX N/A
- KROS N/A
- EPS Growth
- ATEX N/A
- KROS N/A
- EPS
- ATEX N/A
- KROS N/A
- Revenue
- ATEX $5,902,000.00
- KROS $3,550,000.00
- Revenue This Year
- ATEX $49.39
- KROS $16.65
- Revenue Next Year
- ATEX $2.84
- KROS $107.46
- P/E Ratio
- ATEX N/A
- KROS N/A
- Revenue Growth
- ATEX 66.77
- KROS 2250.99
- 52 Week Low
- ATEX $27.37
- KROS $9.78
- 52 Week High
- ATEX $42.91
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- ATEX 53.11
- KROS 44.86
- Support Level
- ATEX $36.50
- KROS $10.62
- Resistance Level
- ATEX $38.95
- KROS $12.28
- Average True Range (ATR)
- ATEX 1.39
- KROS 0.60
- MACD
- ATEX -0.48
- KROS 0.34
- Stochastic Oscillator
- ATEX 27.24
- KROS 51.20
About ATEX Anterix Inc.
Anterix Inc is a United States-based company engaged in delivering broadband needed to modernize infrastructure for energy, transportation, logistics, and other industries. The company offers Private LTE for utilities which help to automate processes, monitor environmental conditions, enable artificial intelligence, and drive productivity.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.